LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Ventyx Biosciences Inc

Closed

2.46 2.5

Overview

Share price change

24h

Current

Min

2.36

Max

2.5

Key metrics

By Trading Economics

Income

1.9M

-27M

EPS

-0.39

Employees

81

EBITDA

2.4M

-30M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+373.03% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

58M

161M

Previous open

-0.04

Previous close

2.46

Ventyx Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Sept 2024, 12:43 UTC

Major Market Movers

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Peer Comparison

Price change

Ventyx Biosciences Inc Forecast

Price Target

By TipRanks

373.03% upside

12 Months Forecast

Average 11.4 USD  373.03%

High 21 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.